 Todd Kingdom
Concepts (349)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 25 | 2021 | 239 | 3.590 |
Why?
| | Rhinitis | 23 | 2023 | 173 | 3.340 |
Why?
| | Nasal Polyps | 15 | 2017 | 61 | 2.990 |
Why?
| | Endoscopy | 21 | 2024 | 327 | 2.640 |
Why?
| | Paranasal Sinuses | 13 | 2017 | 84 | 1.860 |
Why?
| | Paranasal Sinus Neoplasms | 8 | 2024 | 29 | 1.550 |
Why?
| | Dacryocystorhinostomy | 3 | 2020 | 12 | 1.050 |
Why?
| | Surgery, Computer-Assisted | 3 | 2015 | 79 | 0.990 |
Why?
| | Nasal Mucosa | 6 | 2019 | 111 | 0.940 |
Why?
| | Skull Base | 6 | 2023 | 55 | 0.880 |
Why?
| | Aspirin | 6 | 2016 | 385 | 0.840 |
Why?
| | Cystic Fibrosis | 7 | 2014 | 1129 | 0.730 |
Why?
| | Orbit | 4 | 2016 | 70 | 0.680 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 348 | 0.580 |
Why?
| | Lipoxygenase | 2 | 2008 | 18 | 0.540 |
Why?
| | Postoperative Complications | 7 | 2018 | 2824 | 0.540 |
Why?
| | Chronic Disease | 19 | 2023 | 1812 | 0.540 |
Why?
| | Sphenoid Sinus | 2 | 2009 | 11 | 0.520 |
Why?
| | Asthma, Aspirin-Induced | 1 | 2015 | 3 | 0.480 |
Why?
| | Decompression, Surgical | 2 | 2017 | 114 | 0.460 |
Why?
| | Graves Ophthalmopathy | 1 | 2015 | 13 | 0.460 |
Why?
| | Paranasal Sinus Diseases | 3 | 2017 | 16 | 0.440 |
Why?
| | Protein Array Analysis | 2 | 2011 | 56 | 0.380 |
Why?
| | Eosinophilia | 3 | 2016 | 224 | 0.370 |
Why?
| | Respiratory System | 1 | 2013 | 157 | 0.370 |
Why?
| | Bronchiectasis | 1 | 2013 | 113 | 0.370 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 28 | 0.360 |
Why?
| | Middle Aged | 34 | 2024 | 34595 | 0.350 |
Why?
| | Sputum | 1 | 2013 | 311 | 0.350 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 236 | 0.350 |
Why?
| | Rhinitis, Allergic | 4 | 2021 | 42 | 0.350 |
Why?
| | Chemokine CCL5 | 1 | 2011 | 43 | 0.340 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 133 | 0.340 |
Why?
| | Immunotherapy | 1 | 2015 | 644 | 0.330 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 715 | 0.330 |
Why?
| | Tomography, X-Ray Computed | 15 | 2018 | 2765 | 0.330 |
Why?
| | Quality of Life | 6 | 2024 | 3021 | 0.320 |
Why?
| | Humans | 72 | 2024 | 141265 | 0.320 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 27 | 0.320 |
Why?
| | Frontal Sinus | 2 | 2007 | 6 | 0.320 |
Why?
| | Cerebrospinal Fluid Rhinorrhea | 3 | 2022 | 10 | 0.310 |
Why?
| | Surgical Flaps | 3 | 2019 | 144 | 0.310 |
Why?
| | Leiomyosarcoma | 1 | 2009 | 29 | 0.310 |
Why?
| | Adult | 33 | 2024 | 39201 | 0.310 |
Why?
| | Cyclooxygenase 2 | 2 | 2008 | 175 | 0.300 |
Why?
| | Mycoses | 3 | 2005 | 86 | 0.290 |
Why?
| | Odontoma | 1 | 2008 | 4 | 0.290 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2008 | 8 | 0.290 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2008 | 78 | 0.290 |
Why?
| | Retrospective Studies | 22 | 2022 | 16373 | 0.280 |
Why?
| | Treatment Outcome | 15 | 2024 | 11194 | 0.280 |
Why?
| | Aged | 25 | 2024 | 24796 | 0.270 |
Why?
| | Male | 41 | 2024 | 70061 | 0.270 |
Why?
| | Head and Neck Neoplasms | 3 | 2024 | 555 | 0.270 |
Why?
| | Immunoglobulin E | 2 | 2018 | 331 | 0.260 |
Why?
| | Female | 38 | 2024 | 75727 | 0.250 |
Why?
| | Nose Neoplasms | 2 | 1996 | 25 | 0.240 |
Why?
| | Consensus | 3 | 2021 | 546 | 0.240 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 123 | 0.230 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1543 | 0.230 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 19 | 0.230 |
Why?
| | Osteomyelitis | 1 | 2007 | 143 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 2 | 2016 | 122 | 0.220 |
Why?
| | Streptococcus | 1 | 2004 | 29 | 0.220 |
Why?
| | Hypersensitivity | 3 | 2024 | 260 | 0.220 |
Why?
| | Prednisone | 2 | 2017 | 228 | 0.220 |
Why?
| | Staphylococcus | 1 | 2004 | 75 | 0.210 |
Why?
| | Gram-Negative Bacteria | 1 | 2004 | 79 | 0.210 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 4 | 2011 | 39 | 0.210 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2003 | 17 | 0.200 |
Why?
| | Adenoma | 2 | 2018 | 216 | 0.200 |
Why?
| | Skull Base Neoplasms | 1 | 2023 | 31 | 0.200 |
Why?
| | Bone Diseases | 1 | 2003 | 66 | 0.190 |
Why?
| | Aged, 80 and over | 11 | 2024 | 7947 | 0.190 |
Why?
| | Reoperation | 3 | 2019 | 593 | 0.180 |
Why?
| | Pseudomonas aeruginosa | 4 | 2014 | 357 | 0.180 |
Why?
| | Laryngeal Diseases | 2 | 2003 | 32 | 0.170 |
Why?
| | Adolescent | 14 | 2019 | 22064 | 0.170 |
Why?
| | Glucocorticoids | 2 | 2017 | 533 | 0.170 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2020 | 8 | 0.170 |
Why?
| | Nasolacrimal Duct | 1 | 2020 | 10 | 0.170 |
Why?
| | Prospective Studies | 6 | 2024 | 7787 | 0.160 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1493 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 5 | 0.150 |
Why?
| | Nasal Septum | 2 | 2020 | 25 | 0.150 |
Why?
| | Sella Turcica | 1 | 2018 | 17 | 0.150 |
Why?
| | Polyethylenes | 1 | 2018 | 15 | 0.150 |
Why?
| | Parotid Diseases | 1 | 1998 | 4 | 0.150 |
Why?
| | Ethmoid Sinus | 2 | 2015 | 9 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 1998 | 10 | 0.150 |
Why?
| | Up-Regulation | 2 | 2012 | 856 | 0.140 |
Why?
| | Otolaryngology | 2 | 2011 | 106 | 0.140 |
Why?
| | Sclerotherapy | 1 | 1998 | 20 | 0.140 |
Why?
| | Doxycycline | 1 | 1998 | 61 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1726 | 0.140 |
Why?
| | Vision Disorders | 2 | 2017 | 167 | 0.140 |
Why?
| | Immunoglobulin D | 1 | 2017 | 30 | 0.140 |
Why?
| | Mucocele | 1 | 2017 | 13 | 0.130 |
Why?
| | Cysts | 1 | 1998 | 113 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2018 | 143 | 0.130 |
Why?
| | Melanoma | 2 | 1995 | 795 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2015 | 5213 | 0.130 |
Why?
| | Pituitary Neoplasms | 1 | 2018 | 194 | 0.130 |
Why?
| | Aspergillosis | 1 | 1996 | 22 | 0.120 |
Why?
| | Aspergillus fumigatus | 1 | 1996 | 25 | 0.120 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2013 | 22 | 0.120 |
Why?
| | Neuroendoscopy | 1 | 2016 | 24 | 0.120 |
Why?
| | Visual Acuity | 2 | 2017 | 447 | 0.120 |
Why?
| | Graves Disease | 1 | 2016 | 34 | 0.120 |
Why?
| | Th1-Th2 Balance | 1 | 2015 | 8 | 0.120 |
Why?
| | Therapeutic Irrigation | 1 | 2016 | 80 | 0.120 |
Why?
| | Superantigens | 1 | 2015 | 69 | 0.120 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 126 | 0.120 |
Why?
| | Forced Expiratory Volume | 2 | 2014 | 484 | 0.120 |
Why?
| | Pharynx | 1 | 1995 | 61 | 0.120 |
Why?
| | Nasopharynx | 1 | 2015 | 73 | 0.110 |
Why?
| | Mouth | 1 | 1995 | 88 | 0.110 |
Why?
| | Neck | 3 | 2005 | 106 | 0.110 |
Why?
| | Dinoprostone | 1 | 2015 | 189 | 0.110 |
Why?
| | Meningitis | 1 | 2016 | 81 | 0.110 |
Why?
| | Nasal Cavity | 1 | 1995 | 61 | 0.110 |
Why?
| | Actinomycosis | 1 | 1994 | 5 | 0.110 |
Why?
| | Intraoperative Complications | 1 | 2016 | 147 | 0.110 |
Why?
| | Young Adult | 8 | 2018 | 13665 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 430 | 0.110 |
Why?
| | Nose Diseases | 1 | 1994 | 18 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1995 | 217 | 0.110 |
Why?
| | Cervical Vertebrae | 1 | 1995 | 146 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 197 | 0.110 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 393 | 0.100 |
Why?
| | Angiofibroma | 1 | 2013 | 6 | 0.100 |
Why?
| | Pituitary Diseases | 1 | 2013 | 20 | 0.100 |
Why?
| | Microbiota | 3 | 2018 | 759 | 0.100 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2013 | 20 | 0.100 |
Why?
| | Case-Control Studies | 5 | 2017 | 3580 | 0.100 |
Why?
| | Cerebellopontine Angle | 1 | 1993 | 8 | 0.100 |
Why?
| | HIV Seropositivity | 1 | 1994 | 119 | 0.100 |
Why?
| | Biopsy | 3 | 2017 | 1070 | 0.100 |
Why?
| | Granulocytes | 1 | 2013 | 84 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 45 | 0.100 |
Why?
| | Biofilms | 1 | 2015 | 274 | 0.100 |
Why?
| | Chemoreceptor Cells | 1 | 2013 | 53 | 0.100 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.100 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 498 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 306 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 75 | 0.090 |
Why?
| | Skull Neoplasms | 1 | 2012 | 21 | 0.090 |
Why?
| | Neoplasms, Second Primary | 2 | 2012 | 100 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 295 | 0.090 |
Why?
| | Histocytochemistry | 1 | 2011 | 80 | 0.090 |
Why?
| | Cerebrospinal Fluid Leak | 3 | 2022 | 67 | 0.090 |
Why?
| | Pituitary Gland | 1 | 2012 | 151 | 0.090 |
Why?
| | Cerebellar Neoplasms | 1 | 1993 | 179 | 0.090 |
Why?
| | Incidence | 2 | 2015 | 2800 | 0.080 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 347 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2013 | 1074 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2011 | 136 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 418 | 0.080 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 2 | 0.080 |
Why?
| | Caspase 8 | 1 | 2009 | 48 | 0.080 |
Why?
| | Caspase 9 | 1 | 2009 | 57 | 0.080 |
Why?
| | Epistaxis | 3 | 2011 | 17 | 0.080 |
Why?
| | Bacteria | 1 | 2016 | 875 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 6 | 2013 | 3731 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2009 | 188 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 74 | 0.070 |
Why?
| | Drug Tolerance | 1 | 2009 | 105 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 855 | 0.070 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2008 | 18 | 0.070 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2008 | 42 | 0.070 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2008 | 23 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1232 | 0.070 |
Why?
| | Maxilla | 1 | 2007 | 36 | 0.070 |
Why?
| | Child | 9 | 2016 | 22342 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 68 | 0.070 |
Why?
| | Fellowships and Scholarships | 1 | 2011 | 323 | 0.070 |
Why?
| | Reference Values | 1 | 2008 | 805 | 0.060 |
Why?
| | Arnold-Chiari Malformation | 2 | 1997 | 27 | 0.060 |
Why?
| | Child, Preschool | 5 | 2011 | 11473 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 524 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 432 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1865 | 0.060 |
Why?
| | Disease Progression | 1 | 2012 | 2798 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 855 | 0.060 |
Why?
| | Asthma | 2 | 2016 | 1919 | 0.060 |
Why?
| | Risk Assessment | 2 | 2013 | 3515 | 0.050 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5937 | 0.050 |
Why?
| | Pharyngeal Diseases | 1 | 2003 | 17 | 0.050 |
Why?
| | Fungi | 1 | 2005 | 152 | 0.050 |
Why?
| | HIV Infections | 1 | 1998 | 2970 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 4009 | 0.050 |
Why?
| | Mouth Diseases | 1 | 2003 | 46 | 0.050 |
Why?
| | Drug Resistance, Bacterial | 1 | 2004 | 192 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 367 | 0.050 |
Why?
| | Acute Disease | 2 | 2016 | 1012 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1195 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2004 | 167 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2003 | 144 | 0.050 |
Why?
| | United States | 3 | 2015 | 15243 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 527 | 0.050 |
Why?
| | Head | 1 | 2003 | 117 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2072 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2003 | 201 | 0.040 |
Why?
| | Vocal Cord Paralysis | 2 | 1998 | 28 | 0.040 |
Why?
| | Ecchymosis | 1 | 2000 | 3 | 0.040 |
Why?
| | Mitomycin | 1 | 2020 | 33 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 360 | 0.040 |
Why?
| | Orbital Diseases | 1 | 2000 | 32 | 0.040 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2001 | 119 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1865 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2004 | 436 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2022 | 196 | 0.040 |
Why?
| | Absorbable Implants | 1 | 2020 | 35 | 0.040 |
Why?
| | Drug Implants | 1 | 2020 | 82 | 0.040 |
Why?
| | Meningioma | 1 | 2001 | 89 | 0.040 |
Why?
| | Signal Transduction | 1 | 2012 | 5153 | 0.040 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 1998 | 4 | 0.040 |
Why?
| | Tracheal Neoplasms | 1 | 1998 | 12 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 1998 | 34 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2000 | 245 | 0.040 |
Why?
| | Nasal Decongestants | 1 | 2018 | 8 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 20 | 0.030 |
Why?
| | Larynx | 1 | 1998 | 64 | 0.030 |
Why?
| | Skin Tests | 1 | 2018 | 97 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 180 | 0.030 |
Why?
| | Epidemiologic Methods | 1 | 2018 | 94 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2017 | 41 | 0.030 |
Why?
| | Probiotics | 1 | 2018 | 57 | 0.030 |
Why?
| | Plasma Cells | 1 | 2017 | 74 | 0.030 |
Why?
| | Mucus | 1 | 2017 | 78 | 0.030 |
Why?
| | Complementary Therapies | 1 | 2018 | 90 | 0.030 |
Why?
| | Carcinoma | 1 | 1998 | 231 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2905 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 242 | 0.030 |
Why?
| | Candidiasis | 1 | 1996 | 62 | 0.030 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 509 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 288 | 0.030 |
Why?
| | Immunoglobulin A | 1 | 2017 | 215 | 0.030 |
Why?
| | Occupational Diseases | 1 | 2018 | 160 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2017 | 200 | 0.030 |
Why?
| | Chemokines | 1 | 2017 | 228 | 0.030 |
Why?
| | Chondrocalcinosis | 1 | 1995 | 2 | 0.030 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 1995 | 2 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1267 | 0.030 |
Why?
| | Perioperative Period | 1 | 2016 | 69 | 0.030 |
Why?
| | Giant Cell Tumors | 1 | 1995 | 3 | 0.030 |
Why?
| | Odontoid Process | 1 | 1995 | 4 | 0.030 |
Why?
| | Atlanto-Axial Joint | 1 | 1995 | 13 | 0.030 |
Why?
| | Surgical Wound Dehiscence | 1 | 1995 | 22 | 0.030 |
Why?
| | Chondrosarcoma | 1 | 1995 | 17 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2016 | 71 | 0.030 |
Why?
| | Spinal Neoplasms | 1 | 1995 | 36 | 0.030 |
Why?
| | Chordoma | 1 | 1995 | 17 | 0.030 |
Why?
| | Water Microbiology | 1 | 2016 | 88 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2023 | 2923 | 0.030 |
Why?
| | Hemorrhage | 1 | 2000 | 782 | 0.030 |
Why?
| | Spinal Diseases | 1 | 1995 | 51 | 0.030 |
Why?
| | Joint Dislocations | 1 | 1995 | 51 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2018 | 329 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 189 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 232 | 0.030 |
Why?
| | Joint Diseases | 1 | 1995 | 61 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1042 | 0.030 |
Why?
| | Tracheostomy | 1 | 1996 | 142 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 94 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 1995 | 88 | 0.030 |
Why?
| | Biological Products | 1 | 2018 | 239 | 0.030 |
Why?
| | Allergens | 1 | 2018 | 401 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 47 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2015 | 5651 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 501 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 321 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 1998 | 336 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 357 | 0.030 |
Why?
| | Lung Diseases | 1 | 2000 | 793 | 0.030 |
Why?
| | Chlorides | 1 | 2014 | 138 | 0.030 |
Why?
| | Vestibulocochlear Nerve | 1 | 1993 | 7 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 546 | 0.030 |
Why?
| | Facial Nerve | 1 | 1993 | 39 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1312 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3343 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2017 | 899 | 0.020 |
Why?
| | Phospholipase C beta | 1 | 2013 | 29 | 0.020 |
Why?
| | Cranial Nerve Diseases | 1 | 1993 | 42 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2018 | 578 | 0.020 |
Why?
| | Transducin | 1 | 2013 | 42 | 0.020 |
Why?
| | Perioperative Care | 1 | 2015 | 228 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 149 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2013 | 328 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 1995 | 290 | 0.020 |
Why?
| | Angiography | 1 | 2013 | 207 | 0.020 |
Why?
| | Olfaction Disorders | 1 | 2013 | 70 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1492 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2013 | 120 | 0.020 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 229 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 321 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 10482 | 0.020 |
Why?
| | Epithelium | 1 | 2013 | 315 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 2013 | 180 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 714 | 0.020 |
Why?
| | Hematoma | 1 | 2011 | 55 | 0.020 |
Why?
| | Phenylephrine | 1 | 2011 | 75 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2011 | 112 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 226 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 325 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 654 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 149 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 529 | 0.020 |
Why?
| | Survival Rate | 1 | 1995 | 1973 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1323 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1993 | 1243 | 0.020 |
Why?
| | Animals | 1 | 2012 | 37642 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 435 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2093 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1769 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1052 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1398 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1196 | 0.020 |
Why?
| | Workload | 1 | 2011 | 165 | 0.020 |
Why?
| | Societies, Medical | 1 | 2013 | 854 | 0.020 |
Why?
| | Career Choice | 1 | 2011 | 233 | 0.020 |
Why?
| | Down Syndrome | 1 | 1995 | 505 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2095 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 368 | 0.020 |
Why?
| | Pain | 1 | 2013 | 776 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1995 | 1179 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4179 | 0.020 |
Why?
| | Frontal Sinusitis | 1 | 2005 | 3 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1036 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 1993 | 853 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1335 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 1046 | 0.010 |
Why?
| | Lung | 1 | 1996 | 4129 | 0.010 |
Why?
| | Postoperative Care | 1 | 2005 | 280 | 0.010 |
Why?
| | Clinical Competence | 1 | 2011 | 1197 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5802 | 0.010 |
Why?
| | Facial Pain | 1 | 2001 | 13 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2005 | 645 | 0.010 |
Why?
| | Exophthalmos | 1 | 2001 | 17 | 0.010 |
Why?
| | Masks | 1 | 2001 | 66 | 0.010 |
Why?
| | Nasal Obstruction | 1 | 2001 | 27 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 150 | 0.010 |
Why?
| | Headache | 1 | 2001 | 152 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2001 | 122 | 0.010 |
Why?
| | Laryngectomy | 1 | 1998 | 16 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1974 | 0.010 |
Why?
| | Infant | 1 | 2011 | 9801 | 0.010 |
Why?
| | Radiosurgery | 1 | 2001 | 389 | 0.010 |
Why?
| | Algorithms | 1 | 1998 | 1764 | 0.010 |
Why?
|
|
Kingdom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|